Nahdi Medical Company vs Qomel Company
A head-to-head of Nahdi Medical Company (4164) and Qomel Company (9600) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | 4164 | 9600 |
|---|---|---|
| Market Cap | 12.25B SAR | 343.14M SAR |
| P/E (TTM) | 14.23 | 22.46 |
| Forward P/E | 12.90 | — |
| P/S | 1.18 | 2.60 |
| P/B | 4.52 | 2.80 |
| EV/EBITDA | 10.58 | 17.95 |
| Dividend Yield | 637.00% | — |
| Profit Margin | 7.82% | 11.31% |
| Gross Margin | 37.26% | 30.03% |
| Operating Margin | 8.97% | 15.88% |
| Revenue Growth (YoY) | +6.05% | -7.10% |
| FCF Yield | 9.12% | — |
| Debt / Equity | 67.65 | 32.12 |
| Current Ratio | 1.34 | 2.31 |
Which is better: Nahdi Medical Company or Qomel Company?
- ✓Larger by market cap: Nahdi Medical Company
- ✓Cheaper valuation (lower P/E): Nahdi Medical Company
- ✓More profitable (net margin): Qomel Company
- ✓Faster revenue growth: Nahdi Medical Company
Very close — each leads on 5 metrics.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare Nahdi Medical Company with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.